Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  TUMOR IMMUNITY
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Is tumor expression of the major histocompatibility complex antigen required for T cell immune surveillance?

100%
Liu Y., Zheng P.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 2 suppl.
61-64
EN
Tumor expression of major histocompatibility complex antigen (MHC) class I and class II is not essential for the induction of memory T cells. However, induction of MHC class I-restricted effector cytotoxic T cells (CTL) appears dependent on MHC class I expression on tumors. Moreover, the effector function of tumor-specific CTL requires direct recognition of the tumor. In contrast, both the inductive and the effector phases of MHC class II-restricted T cells are independent of MHC class II expression on tumors.
2

The significance of Treg cells in defective tumor immunity

100%
Kosmaczewska A., Ciszak L., Potoczek S., Frydecka I.
Archivum Immunologiae et Therapiae Experimentalis
|
2008
|
vol. 56
|
issue 3
181-191
EN
Regulatory T cells (Treg) enriched in FoxP3+, glucocorticoid-induced TNF receptor+, and cytotoxic T-lymphocyte-associated antigen-4+ exert a potential to suppress effector T cells in the periphery. These cells exist in markedly higher proportions within tumor-infiltrating lymphocytes, peripheral blood lymphocytes, and/or regional lymph node lymphocytes of patients with cancer and their frequencies are suggested to be strongly related to tumor progression and inversely correlated with the efficacy of treatment. Tumor-specific Treg cells require ligand-specific activation and cell-to-cell contact to exert their suppressive activity on tumor-specific effector cells (CD8+ cytotoxic T lymphocytes and CD4+ Th cells), which includes decreased cytotoxity, proliferation, and Th1 cytokine secrection. Depletion or blockade of Treg cells can enhance immune protection from tumor-associated antigens that are expressed as self antigens. Recent studies revealed that lymphoma T cells might adopt a Treg profile as well. Studies assessing the influence of chemotherapy on Treg cells have also been included in this review.
3

Control of immune responses by immunoregulatory T cells

100%
Rudge G., Gleeson P. A., van_ D. J. R.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
vol. 54
|
issue 6
381-391
EN
Immunoregulatory T cells play a key role in modifying the immune responses to self antigens, tumor antigens, and pathogenic organisms. This review summarizes recent data on naturally occurring CD4+ regulatory T cells that constitutively express CD25 (CD25+ Treg). We examine the markers that can be used to differentiate these cells from effector T cells, what is known about their mode of action in controlling the activity of effector T cells, the antigenic specificity of CD25+ Treg, and their ability to survive and to be selected in vivo. We also summarize specific information on the role of CD25+ Treg in controlling anti-tumor responses, an area were manipulation of this subset holds particular clinical promise.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.